Amgen Inc.
Amgen Announces Retirement of CFO Peter Griffith and Appointment of Thomas Dittrich
Summary
On May 19, 2026, Amgen Inc. announced the retirement of Peter H. Griffith, its Executive Vice President and Chief Financial Officer, effective August 31, 2026. Griffith will remain with the company until January 2027 in a non-executive role to ensure a smooth transition. Thomas Dittrich has been appointed as Griffith's successor, effective September 1, 2026. Dittrich, who previously held senior finance roles at Amgen, brings over 30 years of international leadership experience. His compensation package includes an annual base salary, equity awards, and relocation benefits.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement